Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 001540529 approvals65 trials

AHN-GOOK PHARMACEUTICAL Co., Ltd.

Official website

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

As of 2026-10-09, AHN-GOOK PHARMACEUTICAL Co., Ltd. has 58 Korean MFDS device approvals, 471 Korean MFDS drug approvals, 2 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1959, Ahn-Gook Pharmaceutical listed on KOSDAQ in 2000 as a pharmaceutical and health functional food company. It sells the cough/expectorant drug Sinecuran along with Febarozet, Levotension, and Shubazet for the circulatory and respiratory markets, plus the eye-health supplement Tobicom, and diversifies distribution through its online channel 'A-Wonder'. It operates a GMP-certified plant in Hyangnam-eup, Hwaseong, alongside a CMO business, expanded its R&D center to a new Gwacheon headquarters in 2024, and posted consolidated 2025 sales of KRW 306.874 billion (up 13.2% YoY), with Sinecuran and Febarozet accounting for 10.5% and 8.7% of sales respectively.

Products & technology

  • SinecuranCough/expectorant drug
  • FebarozetCirculatory system drug
  • LevotensionCirculatory system drug
  • Shubazet
  • TobicomEye-health supplement

Regulatory approvals

data.go.kr

471 Korean MFDS drug approvals · 1970–2026 / 58 Korean MFDS device approvals · 2005–2022

  • MFDS drugEner-Cit Tab.2026-09-22
    Drug · OTC · Notification202602878
  • MFDS drugPenorexin cap.2026-06-25
    Drug · Prescription · Approval202601808
  • MFDS drugSubsidiary: 안국뉴팜(주)Newdonpizilduo Tab. 10/20mg2026-05-29
    Drug · Prescription · Approval202601570
  • MFDS drugDoneduo Tab. 10/20mg2026-05-13
    Drug · Prescription · Approval202601402
  • MFDS drugLevosartan Plus tab. 2.5/160/2.5mg2026-04-28
    Drug · Prescription · Approval202601268
  • MFDS drugLevosartan Plus tab. 2.5/160/1.25mg2026-04-28
    Drug · Prescription · Approval202601269
  • MFDS drugLevosartan Plus tab. 2.5/80/1.25mg2026-04-28
    Drug · Prescription · Approval202601270
  • MFDS drugSubsidiary: 안국뉴팜(주)NewPharm Pitaeze Tab. 1/10mg2026-04-24
    Drug · Prescription · Approval202601209
  • MFDS drugPevarozet Tab. 1/10mg2026-04-20
    Drug · Prescription · Approval202601147
  • MFDS drugVonopack Tab. 10mg2026-03-06
    Drug · Prescription · Approval202600668
  • MFDS drugVonopack Tab. 20mg2026-03-06
    Drug · Prescription · Approval202600669
  • MFDS drugVitus Tab. 50mg2026-01-19
    Drug · Prescription · Approval202600162
Show 68 more
  • MFDS drugCalmbreat Suspension for Nebulizer2026-01-16
    Drug · Prescription · Approval202600155
  • MFDS drugAlphasidol Soft Cap.0.5μg2025-12-01
    Drug · OTC · Notification202503126
  • MFDS drugPevaro F Tab.2025-08-29
    Drug · Prescription · Approval202502269
  • MFDS drugCiustar Tab. 2.5mg2025-06-12
    Drug · Prescription · Approval202501436
  • MFDS drugDonetia Powd. 5mg, Donetia Powd. 10mg2025-05-30
    Drug · Prescription · Approval202501347
  • MFDS drugDiQvan Tab. 40mg2025-03-27
    Drug · Prescription · Approval202500724
  • MFDS drugBromtella Eye drops2024-11-04
    Drug · Prescription · Approval202402584
  • MFDS drugAvusmet Tab. 50/1000mg2024-05-24
    Drug · Prescription · Approval202401283
  • MFDS drugA-Duta Soft Cap. 0.5mg2024-04-04
    Drug · Prescription · Approval202400769
  • MFDS drugSubsidiary: 안국뉴팜(주)Newginko Tab. 240mg2024-04-01
    Drug · OTC · Notification202400707
  • MFDS drugKano N Tab. 30mg2024-02-29
    Drug · Prescription · Approval202400426
  • MFDS drugOlotella eye drops. 0.2%2024-01-29
    Drug · Prescription · Approval202400217
  • MFDS drugA-diance Duo Tab. 12.5/500mg2023-08-30
    Drug · Prescription · Approval202302580
  • MFDS drugA-diance Duo Tab. 12.5/1000mg2023-08-30
    Drug · Prescription · Approval202302581
  • MFDS drugA-diance Duo Tab. 12.5/850mg2023-08-30
    Drug · Prescription · Approval202302582
  • MFDS drugAhngook Fexofenadine Tab. 60mg2023-08-23
    Drug · OTC · Notification202302507
  • MFDS drugCox2 Plus Tab.2023-08-10
    Drug · Prescription · Approval202302394
  • MFDS drugCarboxtella Eye drops2023-07-05
    Drug · OTC · Notification202302054
  • MFDS drugPevarozet Tab. 4/10mg2023-05-24
    Drug · Prescription · Approval202301661
  • MFDS drugPevarozet Tab. 2/10 mg2023-05-24
    Drug · Prescription · Approval202301662
  • MFDS drugAhn-gook edoxaban Tab. 30mg2023-04-19
    Drug · Prescription · Approval202301280
  • MFDS drugAhn-gook edoxaban Tab. 60mg2023-04-19
    Drug · Prescription · Approval202301281
  • MFDS drugAdapasita Duo Tab. 10/100mg2023-01-19
    Drug · Prescription · Approval202300306
  • MFDS drugSubsidiary: 안국뉴팜(주)New Sitaglozin tab. 10/100mg2023-01-11
    Drug · Prescription · Approval202300197
  • MFDSSubsidiary: 안국바이오진단(주)Clinical chemistry automated analyser2022-12-28
    Product approval · Class 1체외 수신 22-2217 호
  • MFDS drugA-dapa Tab. 5mg2022-12-02
    Drug · Prescription · Approval202204325
  • MFDS drugSubsidiary: 안국뉴팜(주)-2022-11-22
    Drug · Prescription · Approval202204210
  • MFDSSubsidiary: 안국바이오진단(주)IVD Reagents for pregnancy/childbirth hormone and protein tests2022-08-09
    Product approval · Class 2체외 수인 22-4395 호
  • MFDSSubsidiary: 안국바이오진단(주)Chemiluminescence assay(CLIA) analyzer2022-07-06
    Product approval · Class 1체외 수신 22-1166 호
  • MFDS drugLevotitan Tab. 40/10mg2022-06-27
    Drug · Prescription · Approval202202672
  • MFDS drugA-dapa Tab. 10mg2022-05-23
    Drug · Prescription · Approval202202177
  • MFDS drugSubsidiary: 안국뉴팜(주)Newpharmdapagliflozin Tab. 10mg2022-05-23
    Drug · Prescription · Approval202202179
  • MFDS drugAtenel-M SR Tab. 10/500mg2022-05-23
    Drug · Prescription · Approval202202214
  • MFDS drugAtenel-M SR Tab. 10/750mg2022-05-23
    Drug · Prescription · Approval202202215
  • MFDS drugAtenel-M SR Tab. 20/1000mg2022-05-23
    Drug · Prescription · Approval202202216
  • MFDS drugA-sitamet XR Tab. 50/500mg2022-05-13
    Drug · Prescription · Approval202202027
  • MFDS drugA-sitamet XR Tab. 100/1000mg2022-05-13
    Drug · Prescription · Approval202202028
  • MFDS drugA-sitamet XR Tab. 50/1000mg2022-05-13
    Drug · Prescription · Approval202202029
  • MFDS drugSOFILIM EYE DROP2022-05-11
    Drug · OTC · Notification202201921
  • MFDS drugAhngooksugammadex Inj.2022-05-03
    Drug · Prescription · Approval202201789
  • MFDS drugPariem Duo tab. 5/850mg2022-04-04
    Drug · Prescription · Approval202201357
  • MFDS drugPariem Duo Tab. 50/500mg2022-04-04
    Drug · Prescription · Approval202201358
  • MFDS drugPariem Duo tab. 5/1000mg2022-04-04
    Drug · Prescription · Approval202201359
  • MFDS drugAtenel Tab. 20mg2022-01-25
    Drug · Prescription · Approval202200546
  • MFDS drugA-sitamet Tab. 50/850mg2022-01-11
    Drug · Prescription · Approval202200201
  • MFDS drugA-sitamet Tab. 50/1000mg2022-01-11
    Drug · Prescription · Approval202200202
  • MFDS drugA-sitamet Tab. 50/500mg2022-01-11
    Drug · Prescription · Approval202200203
  • MFDS drugSubsidiary: 안국뉴팜(주)Ahngooknewpharm Vildamet tab. 50/500mg2021-10-25
    Drug · Prescription · Approval202107110
  • MFDS drugAvusmet Tab. 50/500mg2021-10-22
    Drug · Prescription · Approval202107078
  • MFDS drugSubsidiary: 안국뉴팜(주)Newpharm Dobesilsan Tab. 500mg2021-10-07
    Drug · Prescription · Approval202106790
  • MFDS drugDobetella tab. 500mg2021-10-06
    Drug · Prescription · Approval202106756
  • MFDSSubsidiary: 안국바이오진단(주)IVD reagents for extracting nucleic acidsRevoked2021-09-17
    Product approval · Class 1체외 수신 21-1761 호
  • MFDSSubsidiary: 안국바이오진단(주)IVD reagents for extracting nucleic acidsRevoked2021-09-17
    Product approval · Class 1체외 수신 21-1760 호
  • MFDSSubsidiary: 안국바이오진단(주)Extractor, nucleic acidRevoked2021-08-31
    Product approval · Class 1체외 수신 21-1639 호
  • MFDSSubsidiary: 안국바이오진단(주)Extractor, nucleic acidRevoked2021-08-31
    Product approval · Class 1체외 수신 21-1637 호
  • MFDSSubsidiary: 안국바이오진단(주)Chemiluminescence assay(CLIA) analyzerRevoked2021-08-31
    Product approval · Class 1체외 수신 21-1634 호
  • MFDSSubsidiary: 안국바이오진단(주)Chemiluminescence assay(CLIA) analyzerRevoked2021-06-23
    Product approval · Class 1체외 수신 21-1164 호
  • MFDS drugSOS tab. 20/800mg2021-06-18
    Drug · Prescription · Approval202104743
  • MFDS drugSubsidiary: 안국뉴팜(주)Esoplus tab. 20/800 mg2021-06-18
    Drug · Prescription · Approval202104753
  • MFDS drugSubsidiary: 안국뉴팜(주)Ahngook New Pharm rivaroxaban tab. 20 mgRevoked2021-05-03
    Drug · Prescription · Approval202103612
  • MFDS drugSubsidiary: 안국뉴팜(주)Ahngook New Pharm rivaroxaban tab. 15 mgRevoked2021-05-03
    Drug · Prescription · Approval202103613
  • MFDS drugSubsidiary: 안국뉴팜(주)Ahngook New Pharm rivaroxaban tab. 10 mgRevoked2021-05-03
    Drug · Prescription · Approval202103614
  • MFDS drugPevaro Tab. 4mg2021-04-29
    Drug · Prescription · Approval202103521
  • MFDS drugAhngook rivaroxaban tab. 20 mgRevoked2021-04-22
    Drug · Prescription · Approval202103309
  • MFDS drugAhngook rivaroxaban tab. 15 mgRevoked2021-04-22
    Drug · Prescription · Approval202103310
  • MFDS drugAhngook rivaroxaban tab. 10 mgRevoked2021-04-22
    Drug · Prescription · Approval202103311
  • MFDS drugPevaro Tab. 1mg2021-03-31
    Drug · Prescription · Approval202102808
  • MFDS drugPariem tab. 10mgRevoked2021-03-05
    Drug · Prescription · Approval202102095

Showing the 80 most recent of 529 records.

Clinical trials

data.go.kr

65 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 36 · Phase 1 18 · Phase 3 10 · Phase 2 1)

  • BioequivalenceAG-23032026-06-15

    1 trial site

  • BioequivalenceAG-23032026-06-15

    1 trial site

  • Phase 1AG23042025-09-19

    2 trial sites

  • BioequivalenceAG-24072025-09-01

    1 trial site

  • BioequivalenceAG2414T2025-05-09

    2 trial sites

  • Phase 3AG20012025-04-08

    10 trial sites

  • Phase 1AG23042025-03-31

    2 trial sites

  • Phase 1AG22032024-12-05

    1 trial site

  • Phase 3AG23042024-09-25

    16 trial sites

  • BioequivalenceAG22022024-04-08

    1 trial site

  • BioequivalenceAG21082023-05-08

    1 trial site

  • BioequivalenceAG16012023-03-16

    1 trial site

Show 53 more
  • Phase 3AGSAVI(AG-1705)2022-04-15

    30 trial sites

  • Bioequivalence클로펙트정(클로피도그렐황산염)2021-09-27

    1 trial site

  • Bioequivalence록시키드정(록시트로마이신)2021-05-14

    1 trial site

  • Bioequivalence라베톤정20밀리그램(라베프라졸나트륨)2021-04-21

    1 trial site

  • Bioequivalence토프리드정(이토프리드염산염)2021-04-09

    1 trial site

  • Bioequivalence안국록소프로펜나트륨정2021-04-09

    1 trial site

  • Phase 1AG18132020-12-17

    2 trial sites

  • Phase 3AGSAVI(AG-1705)2020-11-30

    19 trial sites

  • Bioequivalence클로펙트정(클로피도그렐황산염)2020-11-03

    1 trial site

  • Phase 1AGTZ2020-09-16

    1 trial site

  • Phase 3AGT, AGZ2020-05-20

    19 trial sites

  • Phase 1AG19012019-08-22

    2 trial sites

  • Phase 3AGS2019-08-06

    13 trial sites

  • Phase 1AG17052019-03-11

    1 trial site

  • Phase 3SDR18-P32018-11-07

    1 trial site

  • Phase 1AG17052018-05-04

    1 trial site

  • Bioequivalence칸토넬플러스발포정2018-03-19

    2 trial sites

  • Bioequivalence안국실로스타졸서방정200밀리그램2017-11-24

    2 trial sites

  • Bioequivalence안국실로스타졸서방정200밀리그램2017-11-24

    2 trial sites

  • Phase 1AG-16062017-06-21

    1 trial site

  • Bioequivalence안국빌다글립틴정2017-04-14

    1 trial site

  • Bioequivalence안국빌다메트정50/1000밀리그램2017-03-08

    2 trial sites

  • Phase 1AG15022017-02-01

    1 trial site

  • Bioequivalence안국리나듀오정2.5/1000밀리그램2017-01-26

    2 trial sites

  • Bioequivalence안국레바미피드정(레바미피드)2017-01-12

    1 trial site

  • Bioequivalence안국티카그렐러정90밀리그램2017-01-05

    1 trial site

  • Bioequivalence큐로스트정10밀리그램(몬테루카스트나트륨)2016-12-12

    1 trial site

  • Bioequivalence칸토넬플러스발포정2016-11-29

    2 trial sites

  • Bioequivalence안국오셀타미비르캡슐75밀리그램(오셀타미비르인산염)2016-11-23

    2 trial sites

  • Phase 1AG-16042016-11-10

    1 trial site

  • Bioequivalence안국리나글립틴정2016-11-02

    2 trial sites

  • Bioequivalence안국텔미암로정2016-02-26

    2 trial sites

  • Phase 1AG15022015-11-17

    1 trial site

  • Bioequivalence칸토넬플러스정2015-11-16

    2 trial sites

  • Bioequivalence푸로세틴캡슐(플루옥세틴염산염)[처방변경후]2015-11-04

    2 trial sites

  • Bioequivalence레보모스정 5/40 밀리그램 (변경후)2015-11-02

    1 trial site

  • Phase 1AG15022015-08-31

    1 trial site

  • Bioequivalence레보텐션정5밀리그램2015-05-20

    1 trial site

  • Phase 1LTP402015-04-03

    1 trial site

  • Bioequivalence타다라필오디프스20mg(산제)(가칭)(타다라필)2015-02-24

    2 trial sites

  • Bioequivalence리포액틴정40밀리그램(아토르바스타틴칼슘삼수화물)2014-12-23

    2 trial sites

  • Bioequivalence디스칸에프정2014-08-20

    1 trial site

  • Phase 1AGSAO302정2014-02-05

    1 trial site

  • Phase 1AGB_P12014-01-03

    1 trial site

  • Phase 3레토프라정10밀리그램2013-10-28

    10 trial sites

  • Phase 1레토프라정20밀리그램2013-04-15

    1 trial site

  • Bioequivalence디스칸정2013-04-03

    1 trial site

  • Phase 1레토프라정20밀리그램2013-02-15

    1 trial site

  • Bioequivalence푸로세틴캡슐(플루옥세틴염산염)2013-02-13
  • Phase 3AGR정(루파타딘푸마르산염)2012-07-13

    9 trial sites

  • Bioequivalence이베스딜정150밀리그램(이베사탄)2012-07-02

    2 trial sites

  • Phase 2NRF8032012-05-07

    7 trial sites

  • Phase 3AGP809정2012-03-20

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 14 more trials

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 114 more patents

AI reads

MAA server logs · IP-verified
215
Times AI engines pulled AHN-GOOK PHARMACEUTICAL Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

213
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

125
live 1
Last 7 days
194
live 1
Last 30 days
215
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot205
  • PerplexityPerplexityBot4
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for AHN-GOOK PHARMACEUTICAL Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Boditech Med Inc.19 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

SD BIOSENSOR INC.16 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

GC Medical Science Corporation14 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

DONG-A ST CO.,LTD14 shared

Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.

Sugentech, Inc.12 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

NanoenTek,Inc.10 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

OSANG HEALTHCARE CO.,LTD.9 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

Precision Biosensor Inc.9 shared

KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.

HUMASIS CO., LTD.8 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

GENEMATRIX INC.8 shared

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

PCL. Inc7 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

CALTH. Inc6 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition